#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
preLekára.sk / Journals / Internal Medicine / 2019 - 7-8

Presepsin in the diagnostics of sepsis

Česká verzia

Authors: Marcela Káňová 1,2,3;  Radim Dobiáš 4,5;  Kateřina Liszková 1;  Michal Frelich 1,2;  Renáta Ječmínková 6;  Roman Kula 1,2
Authors place of work: Klinika anesteziologie, resuscitace a intenzivní medicíny LF OU a FN Ostrava 1;  Katedra intenzivní medicíny, urgentní medicíny a forenzních oborů LF OU Ostrava 2;  Ústav fyziologie a patofyziologie LF OU, Ostrava 3;  Centrum klinických laboratoří, Oddělení bakteriologie a mykologie, Zdravotní ústav se sídlem v Ostravě 4;  Ústav mikrobiologie LF UP v Olomouci 5;  Oddělení centrálního příjmu, Urgentní příjem FN Ostrava 6
Published in the journal: Vnitř Lék 2019; 65(7-8): 497-505
Category:

Summary

Sepsis remains one of the most common causes of death worldwide. It is caused by a complex of inadequate host responses to infection. It is also often difficult to distinguish sepsis from a non-infectious cause of systemic inflammatory response syndrome. Early identification of an infectious origin may dramatically help to improve the outcome and reduce mortality. That is the main reason why clinicians need fast, reliable and specific biomarkers for recognition of sepsis. Presepsin (sCD-14ST) is one of promising biomarkers, the level of which increases in response to a microbial infection in the host. As a glycoprotein expressed in the membranes of monocytes and macrophages, CD14 (cluster of differentiation 14) serves especially as a co-receptor of the lipopolysaccharide-lipopolysaccharide binding protein complexes, and activates the inflammatory cascade. Consequently, during the inflammatory reaction, sCD14-ST, known as presepsin, is cleaved away from plasma. The objective of this article is to determine the diagnostic value of presepsin in the diagnostics of sepsis, assessing its severity, and monitoring the effectiveness of therapeutic interventions, and to establish the prognostic value of this biomarker.

Keywords:

biomarker – intraindividual biological variation

Zdroje
  1. Singer M, Deutschman CS, Seymour CW et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis 3). JAMA 2016; 315(8): 801–810. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2016.0287>.
  2. Fleishmann C, Thomas-Rueddel DO, Hartmann M et al. Hospital incidence and mortality rates of sepsis. An analysis of hospital episode (DRG) statistics in Germany from 2007 to 2013. Dtsch Arztebl Int 2016; 113(10): 159–166. Dostupné z DOI: <http://dx.doi.org/10.3238/arztebl.2016.0159>.
  3. Horák J, Harazim M, Karvunidis T et al. Sepse – jak ji poznat, na co se zaměřit aneb zpět k základům ve světle nové definice. Vnitř Lék 2016; 62(7–8): 568–574.
  4. Dobias R, Jaworska P, Tomaskova H et al. Diagnostic value of serum galactomannan, (1–3)-beta-D-glucan, and Aspergillus fumigatus-specific IgA and IgG assays for invasive pulmonary aspergillosis in non-neutropenic patients. Mycoses 2018; 61(8): 576–586. Dostupné z DOI: <http://dx.doi.org/10.1111/myc.12765>.
  5. Wu J, Hu L, Zhang G et al. Accuracy of presepsin in sepsis diagnosis: A systemic review and meta-analysis. PLoS One 2015; 10(7): e0133057. Dostupné z DOI: <http://dx.doi.org/10.1371/journal.pone.0133057>.
  6. Zhang J, Hu ZD, Song J et al. Diagnostic value of presepsin for sepsis. A systematic review and meta-analysis. Medicine (Baltimore) 2015; 94(47): e2158. Dostupné z DOI: <http://dx.doi.org/10.1097/MD.0000000000002158>.
  7. Liu Y, Hou J, Li Q et al. Biomarkers for diagnosis of sepsis in patients with systematic inflammatory response syndrome: a systematic review and meta-analysis. Springerplus 2016; 5(1): 2091. Dostupné z DOI: <http://dx.doi.org/10.1186/s40064–016–3591–5>
  8. Chenevier-Gobeaux C, Borderie D, Weiss N et al. Presepsin (sCD14-ST), an innate immune response marker sepsis. Clin Chim Acta 2015; 450: 97–103. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cca.2015.06.026>.
  9. Zanoni I, Granucci F. Role of CD14 in host protection against infections and in metabolism regulation. Front Cell Infect Microbiol 2013; 3: 32. Dostupné z DOI: <http://dx.doi.org/10.3389/fcimb.2013.00032>.
  10. Taghavi M, Khosravi A, Mortaz E et al. Role of pathogen-associated molecular patterns (PAMPS) in immune responses to fungal infections. Eur J Pharmacol 2017; 808: 8–13. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ejphar.2016.11.013>.
  11. Ackland GL, Prowle JR. Presepsin: solving a soluble (CD14) problem in sepsis? Intensive Care Med 2015; 41(2): 351–353. Dostupné z DOI: <http://dx.doi.org/10.1007/s00134–014–3642–8>.
  12. Bomberg H, Klingele M, Wagenpfeil S et al. Presepsin (sCD14-ST) is a novel marker for risk stratification in Cardiac surgery patients. Anesthesiology 2017; 126(4): 631–642. Dostupné z DOI: <http://dx.doi.org/10.1097/ALN.0000000000001522>.
  13. Masson S, Caironi P, Fanizza C et al. Circulating presepsin (soluble CD14 subtype) as a marker of host response in patients with severe sepsis or septic shock: data from multicenter, randomized ALBIOS trial. Intensive Care Med 2015; 41(1): 12–20. Dostupné z DOI: <http://dx.doi.org/10.1007/s00134–014–3514–2>.
  14. Wrigley BJ, Lip GY, Shantsila E. The role of monocytes and inflammation in the pathophysiology of heart failure. Eur J Heart Fail 2011; 13(11): 1161–1171. Dostupné z DOI: <http://dx.doi.org/10.1093/eurjhf/hfr122>.
  15. Syrovátka P, Kraml P. Infekce a ateroskleróza. Vnitř Lék 2007; 53(3): 286–291.
  16. Shozushima T, Takahashi G, Matsumoto N et al. Usefulness of presepsin (sCD14-ST) measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome. J Infect Chemother 2011; 17(6): 764–769. Dostupné z DOI: <http://dx.doi.org/10.1007/s10156–011–0254-x>.
  17. Rogić D, Juroš GF, Petrik J et al. Advances and pitfalls in using laboratory biomarkers for the diagnosis and management of sepsis. EJIFCC 2017; 28(2): 114–121.
  18. Chenevier-Gobeaux C, Bardet V, Poupet H et al. Presepsin (sCD14-ST) secretion and kinetics by peripheral blood mononuclear cells and monocytic THP-1 cell line. Ann Biol Clin 2016; 74(1): 93–97. Dostupné z DOI: <http://dx.doi.org/10.1684/abc.2015.1112>.
  19. Sager R, Kutz A, Mueller B et al. Procalcitonin-guided diagnosis and antibiotic stewardship revisited. BMC Med 2017; 15(1): 15. Dostupné z DOI: <http://dx.doi.org/10.1186/s12916–017–0795–7>.
  20. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340(6): 448–454. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJM199902113400607>.
  21. Endo S, Suzuki Y, Takahashi G et al. Usefulness of presepsin in the diagnosis of sepsis in a multicenter prospective study. J Infect Chemother 2012; 18(6): 891–897. Dostupné z DOI: <http://dx.doi.org/10.1007/s10156–012–0435–2>.
  22. Carpio R, Zapata J, Spanuth E et al. Utility of presepsin (sCD14-ST) as a diagnostic and prognostic marker of sepsis in the emergency department. Clin Chim Acta 2015; 450: 169–175. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cca.2015.08.013>.
  23. Bouadma L, Luyt CE, Tubach F et al. Use of procalcitonin to reduce patients´ exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010; 375(9713): 463–474. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(09)61879–1>.
  24. Giavarina D, Carta M. Determination of reference interval for presepsin, an early marker for sepsis. Biochem Med 2015; 25(1): 64–68. Dostupné z DOI: <http://dx.doi.org/10.11613/BM.2015.007>.
  25. Hayashida K, Kondo Y, Hara Y et al. Head-to-head comparison of procalcitonin and presepsin for the diagnosis of sepsis in critically ill adult patients: a protocol for a systematic review and meta-analysis. BMJ Open 2017; 7(3): e014305. Dostupné z DOI: <http://dx.doi.org/10.1136/bmjopen-2016–014305>.
  26. Behnes M, Bertsch T, Lepiorz D et al. Diagnostic and prognostic utility of soluble CD14 subtype (presepsin) for severe sepsis and septic shock during the first week of intensive care treatment. Crit Care 2014; 18(5): 507. Dostupné z DOI: <http://dx.doi.org/10.1186/s13054–014–0507-z>.
  27. Liu B, Chen YX,Yin Q et al. Diagnostic value and prognostic evaluation of Presepsin for sepsis in an emergency department. Crit Care 2013; 17(5): R244. Dostupné z DOI: <http://dx.doi.org/10.1186/cc13070>.
  28. de Guadiana Romualdo LG, Torrella PE, Acebes SR et al. Diagnostic accuracy of presepsin (sCD14-ST) as a biomarker of infection and sepsis in the emergency department. Clin Chim Acta 2017; 464: 6–11. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cca.2016.11.003>.
  29. Pizzolato E, Ulla M, Galluzzo C et al. Role of presepsin for the evaluation of sepsis in the emergency department. Clin Chem Lab Med 2014; 52(10): 1395–1400. Dostupné z DOI: <http://dx.doi.org/10.1515/cclm-2014–0199>.
  30. Pugni L, Pietrasanta C, Milani S et al. Presepsin (soluble CD14 subtype): reference ranges of a new sepsis marker in term and preterm neonates. PLoS One 2015; 10(12): e0146020. Dostupné z DOI: <http://dx.doi.org/10.1371/journal.pone.0146020>.
  31. Stojewska M, Behrendt J, Szymanska A et al. Diagnostic value of presepsin (Scd14-St Subtype) evaluation in the detection of severe neonatal infections. Int J Res Stud Biosci (IJRSB) 2015; 3(1): 110–116.
  32. Chiesa C, Natale F, Pascone R at al. C reactive protein and procalcitonin: reference intervals for preterm and term newborns during the early neonatal period. Clin Chim Acta 2011; 412(11–12): 1053–1059. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cca.2011.02.020>.
  33. Arora S, Singh P, Singh PM et al. Procalcitonin levels in survivors and nonsurvivors of sepsis: systematic review and meta-analysis. Shock 2015; 43(3): 212–221. Dostupné z DOI: <http://dx.doi.org/10.1097/SHK.0000000000000305>.
  34. Liu D, Su L, Han G et al. Prognostic value of procalcitonin in adult patients with sepsis: a systematic review and meta-analysis. PLoS One 2015; 10(6): e0129450. Dostupné z DOI: <http://dx.doi.org/10.1371/journal.pone.0129450>.
  35. Yang HS, Hur M, Yi A et al. Prognostic value of presepsin in adult patients with sepsis: systematic review and meta-analysis. PLoS One 2018; 13(1): e0191486. Dostupné z DOI: <http://dx.doi.org/10.1371/journal.pone.0191486>.
  36. Kim H, Hur M, Moon HW et al. Mutli-marker approach using procalcitonin, presepsin, galectin-3, and soluble suppression of tumorigenicity 2 for the prediction of mortality in sepsis. Ann Intensive Care 2017; 7(1): 27. Dostupné z DOI: <http://dx.doi.org/10.1186/s13613–017–0252-y>.
  37. Beňovská M, Bučková D, Petříková D et al. Presepsin jako diagnostický a prognostický nástroj při posuzování sepse. Klin Biochem Metab 2015; 23(3): 89–94. Dostupné z WWW: <http://www.cskb.cz/res/file/KBM-pdf/2015/2015–3/KBM-3–2015–89-Benovska.pdf>.
  38. Brodská H, Malíčková K, Adámková V et al. Significantly higher procalcitonin levels could differentiate gram-negative sepsis form gram-positive and fungal sepsis. Clin Exp Med 2013; 13(3):165–170. Dostupné z DOI: <http://dx.doi.org/10.1007/s10238–012–0191–8>.
  39. Lu B, Zhang Y, Li C et al. The utility of presepsin in diagnosis and risk stratification for the emergency patients with sepsis. Am J Emerg Med 2018; 36(8): 1341–1345. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ajem.2017.12.038>.
  40. Qi ZJ, Yu H, Zhang J et al. Presepsin as a novel diagnostic biomarker for differentiating active pulmonary tuberculosis from bacterial community acquired pneumonia. Clin Chim Acta 2018; 478: 152–156. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cca.2017.12.045>.
  41. Franeková J, Sečník P, Lavríková P et al. Serial measurement of presepsin, procalcitonin, and C-reactive protein in the early postoperative period and the response to antithymocyte globulin administration after heart transplantation. Clin Transplant 2017; 31(1): e12870. Dostupné z DOI: <http://dx.doi.org/10.1111/ctr.12870.
  42. Nagata T, Yasuda Y, Ando M et al. Clinical impact of kidney function on presepsin levels. PLoS One 2015; 10(6): e0129159. Dostupné z DOI: <http://dx.doi.org/10.1371/journal.pone.0129159>.
  43. Nakamura Y, Ishikura H, Nishida T et al. Usefulness of presepsin in the diagnosis of sepsis in patients with or without acute kidney injury. BMC Anesthesiol 2014; 14: 88. Dostupné z DOI: <http://dx.doi.org/10.1186/1471–2253–14–88>.
  44. Shiota J. Changes of early sepsis biomarker presepsin level during hemodialysis: influence of β2-microglobulin clearance of dialysis membrane: a preliminary study. Kidney Dis (Basel) 2019; 5(1): 43–50. Dostupné z DOI: <https://doi.org/10.1159/000493505>.
  45. Honore PM, Jacobs R, Hendrickx I et al. ‘Biomarking’ infection during continuous renal replacement therapy, still relevant? Crit Care 2015; 19: 232. Dostupné z DOI: <http://dx.doi.org/10.1186/s13054–015–0948-z>.
  46. Hunáková A, Bíla M, Štefanec F. Presepsín – perspektívny marker v diagnostike sepsy diagnostické vlastnosti, benefity a limity. Zdravotnícke listy 2013; 3(1): 4–15.
  47. Hunáková A, Košťál P, Bíla M et al. Presepsín – špecifické limity v diagnostike sepsy: presepsín novorodencov a u pacientov v pokročilom štádiu chronickej renálnej insuficiencie. Zdravotnícke listy 2013; 3(1): 16–22.
  48. Novelli G, Morabito V, Ferretti G et al. Pathfast presepsin assay for early diagnosis of bacterial infections in surgical patients: preliminary study. Transplant Proc 2013; 45(7): 2750–2753. Dostupné z DOI: <http://dx.doi.org/10.1016/j.transproceed.2013.07.021>.
  49. Cikot M, Kasapoglu P, Isiksacan N et al. The importance of presepsin value in detection of gastrointestinal anastomotic leak: a pilot study. J Surg Res 2018; 228: 100–106. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jss.2018.02.059>.
  50. Okamura Y, Yokoi H. Development of point-of-care assay system for measurement of presepsin (sCD14-ST). Clin Chim Acta 2011; 412(23–24): 2157–2161. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cca.2011.07.024>.
Štítky
Diabetology Endocrinology Internal medicine
Článek Vitamin D supplementation dose needs to be higher in patients with inflammatory bowel disease: interventional study
Článek Pulmonary embolism: retrospective view at known disease
Článek Stress within preventive cardiology
Článek Presepsin: what is important for correct interpretation
Článek Je to sepse, nebo není? A je presepsin tou správnou odpovědí? – editorial
Článek Aortic dissection and other acute aortic syndromes in the emergency department
Článek Non-hematogenic activity of erythropoietin
Článek Idiopathic inflammatory bowel disease and the first type of autoimmune form of pancreatitis: case report
Článek Diosmin – still an important modality in the treatment of venous insufficiency
Článek Jiří Beneš. Antibiotika – systematika, vlastnosti, použití
Článok vyšiel v časopise

Internal Medicine

Číslo 7-8
2019 Číslo 7-8
Najčítanejšie tento týždeň
Najčítanejšie v tomto čísle
Prihlásenie
Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.

Prihlásenie

Nemáte účet?  Registrujte sa

#ADS_BOTTOM_SCRIPTS#